Change in oligomerization specificity of the p53 tetramerization domain by hydrophobic amino acid substitutions

Protein Science

Volumn 8, Issue 9, 1999, Pages 1773-1779

  Stavridi, Elena S ^a   Chehab, Nabil H ^a,b   Caruso, Loretta C ^a   Halazonetis, Thanos D ^a,b  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Hydrophobic effect; Oligomerization specificity; p53 tumor suppressor; Protein design

Indexed keywords

AMINO ACID; PROTEIN P53;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER CELL; CANCER INHIBITION; GENE THERAPY; HYDROPHOBICITY; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INTERACTION;

EID: 0032858397     PISSN: 09618368     EISSN: None     Source Type: Journal    
DOI: 10.1110/ps.8.9.1773     Document Type: Article

References (49)

1. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. 1990. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:912-915.
2. Bargonetti J, Manfredi JJ, Chen X, Marshak DR, Prives C. 1993. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev 7:2565-2574.
3. Bargonetti J, Reynisdottir I, Friedman PN, Prives C. 1992. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. Genes Dev 6:1886-1898.
4. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH. 1993. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852.
5. Clore GM, Ernst J, Clubb R, Omichinski JG, Kennedy WM, Sakaguchi K, Appella E, Gronenborn AM. 1995. Refined solution structure of the oligomerization domain of the tumor suppressor p53. Nat Struct Biol 2:321-333.
6. Clore GM, Omichinski JG, Sakaguchi K, Zambrano N, Sakamoto H, Appella E, Gronenborn AM. 1994. High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science 265:386-391.
7. Conseiller E, Debussche L, Landais D, Venot C, Maratrat M, Sierra V, Tocque B, Bracco L. 1998. CTS1: A p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties. J Clin Invest 101:120-121.
8. Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker SJ, Vogelstein B, Friend SH. 1990. p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 10:5772-5781.
9. Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M. 1989. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA 86:8763-8767.
10. Favrot M, Coll JL, Louis N, Negoescu A. 1998. Cell death and cancer: Replacement of apoptotic genes and inactivation of death suppressor genes in therapy. Gene Therapy 5:728-739.
11. Fields S, Jang SK. 1990. Presence of a potent transcription activating sequence in the p53 protein. Science 249:1046-1049.
12. Finlay CA, Hinds PW, Levine AJ. 1989. The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083-1093.
13. Hainaut P, Hall A, Milner J. 1994. Analysis of p53 quaternary structure in relation to sequence-specific DNA binding. Oncogene 9:299-303.
14. Halazonetis TD, Kandil AN. 1993. Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J 12:5057-5064.
15. Hedrick JL, Smith AJ. 1968. Size and charge isomer separation and estimation of molecular weights of proteins by disc gel electrophoresis. Arch Bioch Bioph 126:155-164.
16. Hollstein M, Sidransky D, Vogelstein B, Harris CC. 1991. p53 mutations in human cancers. Science 253:49-53.
17. Jeffrey PD, Gorina S, Pavletich NP. 1995. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 Å. Science 267:1498-1502.
18. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B. 1992. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256:827-830.
19. Kohn WD, Kay CM, Hodges RS. 1998. Orientation, positional, additivity, and oligomerization-state effects of interhelical ion pairs in alpha-helical coiled coils. J Mol Biol 283:993-1012.
20. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. 1992. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491-7495.
21. Landschulz WH, Johnson PF, McKnight SL. 1988. The leucine zipper: A hypothetical structure common to a new class of DNA binding proteins. Science 240:1759-1764.
22. Lee W, Harvey TS, Yin Y, Yau P, Litchfield D, Arrowsmith CH, 1994. Solution structure of the tetrameric minimum transforming domain of p53. Nat Struct Biol 1:877-890.
23. Levine AJ. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
24. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. 1993. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-849.
25. Lumb KJ, Kim PS. 1995. Measurement of interhelical electrostatic interactions in the GCN4 leucine zipper. Science 268:436-439.
26. Martinez J, Georgoff I, Martinez J, Levine AJ. 1991. Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev 5:151-159.
27. McCoy M, Stavridi ES, Waterman JL, Wieczorek AM, Opella SJ, Halazonetis TD. 1997. Hydrophobic side chain size is a determinant of the three-dimensional structure of the p53 oligomerization domain. EMBO J 16:6230-6236.
28. Mercer WE, Shields MT, Amin M, Sauve GJ, Appella E, Romano JW, Ullrich SJ. 1990. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci USA 87:6166-6170.
29. Milner J, Medcalf EA. 1991. Cotranslation of activated mutant p53 with wild-type drives the wild-type p53 protein into the mutant conformation. Cell 65:765-774.
30. Nielsen LL, Maneval DC. 1998. P53 tumor suppressor gene therapy for cancer. Cancer Gene Therapy 5:52-63.
31. O'Shea EK, Klemm JD, Kim PS, Alber T. 1991. X-ray structure of the GCN4 leucine zipper, a two-stranded, parallel coiled coil. Science 254:539-544.
32. O'Shea EK, Rutkowski R, Kim PS. 1989. Evidence that the leucine zipper is a coiled coil. Science 243:538-542.
33. O'Shea EK, Rutkowski R, Kim PS. 1992. Mechanism of specificity in the Fos-Jun oncoprotein heterodimer. Cell 68:699-708.
34. Pietenpol JA, Tokino T, Thiagalingam S, el-Deiry WS, Kinzler KW, Vogelstein B. 1994. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci USA 91:1998-2002.
35. Reed M, Wang Y, Mayr G, Anderson ME, Schwedes JF, Tegtmeyer P. 1993. p53 domains: Suppression, transformation, and transactivation. Gene Expression 3:95-107.
36. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, et al. 1996. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 2:985-991.
37. Sakamoto H, Lewis MS, Kodama H, Appella E, Sakaguchi K. 1994. Specific sequences from the carboxyl terminus of human p53 gene product form antiparallel tetramers in solution. Proc Natl Acad Sci USA 91:8974-8978.
38. Shaulian E, Zauberman A, Ginsberg D, Oren M. 1992. Identification of a minimal transforming domain of p53: Negative dominance through abrogation of sequence-specific DNA binding. Mol Cell Biol 12:5581-5592.
39. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. 1992. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 89:4495-4499.
40. Soussi T, May P. 1996. Structural aspects of the p53 protein in relation to gene evolution: A second look. J Mol Biol 260:623-637.
41. Unger T, Mietz JA, Scheffner M, Yee CL, Howley PM. 1993. Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression. Mol Cell Biol 13:5186-5194.
42. Wang P, Reed M, Wang Y, Mayr G, Stenger JE, Anderson ME, Schwedes JF, Tegtmeyer P. 1994. p53 domains: Structure, oligomerization, and transformation. Mol Cell Biol 14:5182-5191.
43. Waterman JL, Shenk JL, Halazonetis TD. 1995. The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding. EMBO J 14:512-519.
44. Waterman MJ, Stavridi ES, Waterman JL, Halazonetis TD. 1998. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat Genet 19:175-178.
45. Waterman MJ, Waterman JL, Halazonetis TD. 1996. An engineered four-stranded coiled coil substitutes for the tetramerization domain of wild-type p53 and alleviates transdominant inhibition by tumor-derived p53 mutants. Cancer Res 56:158-163.
46. Wieczorek AM, Waterman JL, Waterman MJ, Halazonetis TD. 1996. Structure-based rescue of common tumor-derived p53 mutants. Nat Med 2:1143-1146.
47. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. 1991. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352:345-347.
48. Zeng X, Herndon AM, Hu JC. 1997a. Buried asparagines determine the dimerization specificities of leucine zipper mutants. Proc Natl Acad Sci USA 94:3673-3678.
49. Zeng X, Zhu H, Lashuel HA, Hu JC. 1997b. Oligomerization properties of GCN4 leucine zipper e and g position mutants. Protein Sci 6:2218-2226.